Applied Clinical Trials
ISR's research consistently finds that a CRO's Project Manager often makes the difference between winning and losing a project for the service provider. Not only the number of years experience, or the number of similar projects managed, but also the communication skills and style demonstrated throughout the bidding process.
ISR's research consistently finds that a CRO's Project Manager often makes the difference between winning and losing a project for the service provider. Not only the number of years experience, or the number of similar projects managed, but also the communication skills and style demonstrated throughout the bidding process.
Sponsors Rate Project Manager Quality
In a recent study of the central labs market (See: The State of the Central Labs Market; www.isrreports.com) the impact that a Project Manager has on sponsors' experiences throughout the delivery of a project was examined. This chart illustrates the high degree to which central lab project management is correlated with overall delivery quality (although the brands are obscured in this article). Service providers with highly rated PMs also tend to receive higher overall quality ratings.
If you are a service provider and want to differentiate your offering based on quality, then hire and train the best Project Managers you can find. If you are a sponsor and you want the highest quality central lab experience, then make sure you get the service provider's best Project Managers.
—Industry Standard Research, www.isrreports.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.